News

This study of GRN163L as a single agent is one of six ongoing clinical trials recruiting from 18 US medical centers examining the safety, tolerability, pharmacokinetics and pharmacodynamics

These results, which confirm the findings from the two previous Phase III trials, showed that milnacipran demonstrated a highly statistically significant difference to placebo in responder analyses based

The study involved elderly patients with acute myeloid leukemia (AML), who often have limited options due to comorbidities and are typically considered ineligible for standard induction chemotherapy. Data

GDC-0449 will be evaluated in approximately 100 patients with ovarian cancer in second or third complete remission in a randomized, placebo-controlled, double-blind, multi-center Phase II trial. Patients will

Tetrabenazine will be marketed as Nitoman in Spain by Cambridge’s marketing partner UCB upon successful completion of all related procedures. It has been approved for the treatment of

Results presented demonstrated that p110, whose expression under normal conditions is largely restricted to leukocytes, was highly expressed in more than 90% of hematologic cancer cell lines, including

Dapagliflozin, one of two investigational drugs under joint development by the companies, is currently being studied in Phase III clinical trials in several countries, including the US, to

Elestrin is indicated in the US for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause. PharmaSwiss is responsible for regulatory and marketing activities in Israel.

The event is expected to be attended by 40 senior-level pharmaceutical leaders to discuss the drivers for change in pharma and how they can move and change quickly